HK1171024A1 - 用於表達 多肽的癌症的肽疫苗 - Google Patents
用於表達 多肽的癌症的肽疫苗Info
- Publication number
- HK1171024A1 HK1171024A1 HK12111314.2A HK12111314A HK1171024A1 HK 1171024 A1 HK1171024 A1 HK 1171024A1 HK 12111314 A HK12111314 A HK 12111314A HK 1171024 A1 HK1171024 A1 HK 1171024A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- mphosph1
- polypeptides
- peptide vaccines
- cancers expressing
- cancers
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 229940023041 peptide vaccine Drugs 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Reproductive Health (AREA)
- Physics & Mathematics (AREA)
- Physical Education & Sports Medicine (AREA)
- Plant Pathology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85257506P | 2006-10-17 | 2006-10-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1171024A1 true HK1171024A1 (zh) | 2013-03-15 |
Family
ID=39313729
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK09110942.9A HK1131169A1 (en) | 2006-10-17 | 2009-11-23 | Peptide vaccines for cancers expressing mphosph1 or depdc1 polypeptides |
HK12111316.0A HK1171026A1 (zh) | 2006-10-17 | 2009-11-23 | 用於表達 多肽的癌症的肽疫苗 |
HK12111315.1A HK1171025A1 (zh) | 2006-10-17 | 2009-11-23 | 用於表達 多肽的癌症的肽疫苗 |
HK12111314.2A HK1171024A1 (zh) | 2006-10-17 | 2009-11-23 | 用於表達 多肽的癌症的肽疫苗 |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK09110942.9A HK1131169A1 (en) | 2006-10-17 | 2009-11-23 | Peptide vaccines for cancers expressing mphosph1 or depdc1 polypeptides |
HK12111316.0A HK1171026A1 (zh) | 2006-10-17 | 2009-11-23 | 用於表達 多肽的癌症的肽疫苗 |
HK12111315.1A HK1171025A1 (zh) | 2006-10-17 | 2009-11-23 | 用於表達 多肽的癌症的肽疫苗 |
Country Status (18)
Country | Link |
---|---|
US (5) | US8557955B2 (zh) |
EP (7) | EP2695895A1 (zh) |
JP (2) | JP5339292B2 (zh) |
KR (4) | KR101493773B1 (zh) |
CN (5) | CN102850435B (zh) |
AU (1) | AU2007311395B2 (zh) |
BR (1) | BRPI0717651A2 (zh) |
CA (2) | CA2915560A1 (zh) |
DK (1) | DK2091965T3 (zh) |
ES (4) | ES2545818T3 (zh) |
HK (4) | HK1131169A1 (zh) |
IL (4) | IL198186A (zh) |
MX (1) | MX2009004147A (zh) |
PL (1) | PL2091965T3 (zh) |
PT (1) | PT2091965E (zh) |
RU (1) | RU2469044C2 (zh) |
SG (2) | SG10201502098YA (zh) |
WO (1) | WO2008047473A1 (zh) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2295601A1 (en) | 2005-02-10 | 2011-03-16 | Oncotherapy Science, Inc. | Method of diagnosing bladder cancer |
ES2632123T3 (es) * | 2007-08-20 | 2017-09-11 | Oncotherapy Science, Inc. | Péptido CDH3 y agente medicinal que comprende el mismo |
JP5640263B2 (ja) * | 2008-08-28 | 2014-12-17 | オンコセラピー・サイエンス株式会社 | Depdc1ポリペプチドを使用した膀胱癌の治療または予防のための方法 |
BRPI1012312A2 (pt) * | 2009-03-04 | 2017-03-21 | Oncotherapy Science Inc | peptídeos vangl1 e vacinas incluindo os mesmos |
TW201211250A (en) * | 2010-09-07 | 2012-03-16 | Oncotherapy Science Inc | VANGL1 peptides and vaccines including the same |
KR102015648B1 (ko) * | 2011-08-12 | 2019-08-28 | 온코세라피 사이언스 가부시키가이샤 | Mphosph1 펩티드 및 이를 포함한 백신 |
JP2013058294A (ja) * | 2011-09-09 | 2013-03-28 | Toshiba Corp | 磁気記録媒体及び磁気記録媒体の製造方法 |
SG11201405578TA (en) | 2012-03-09 | 2014-11-27 | Oncotherapy Science Inc | Pharmaceutical composition containing peptide |
JP6041297B2 (ja) * | 2012-08-24 | 2016-12-07 | 国立大学法人山口大学 | 犬リンパ腫の診断方法及び診断キット |
BR112015022189A2 (pt) * | 2013-03-13 | 2017-11-21 | Katsura Misako | microvesícula, método para produção e uso da mesma |
JP6696969B2 (ja) | 2014-04-16 | 2020-05-20 | ユノ・セラピューティクス・ゲーエムベーハーJuno Therapeutics Gmbh | 細胞の集団を拡大する方法、キット、及び装置 |
DK3205661T3 (da) * | 2014-10-07 | 2021-08-02 | Cytlimic Inc | Hsp70-afledt immunitetsinducerende peptid |
EP3207936B1 (en) * | 2014-11-18 | 2021-04-21 | Shionogi & Co., Ltd. | Stable peptide composition |
DK3269733T3 (da) | 2015-03-09 | 2020-07-27 | Cytlimic Inc | Peptid afledt af gpc3, farmaceutisk sammensætning til behandling eller forebyggelse af cancer under anvendelse deraf, immunitetsinducer og fremgangsmåde til fremstilling af antigenpræsenterende celler |
RU2709015C2 (ru) | 2015-04-07 | 2019-12-13 | Ситлимик Инк. | Лекарственное средство |
RU2022100330A (ru) | 2015-08-12 | 2022-01-19 | Онкотерапи Сайенс, Инк. | Пептид, полученный из depdc1, и содержащая его вакцина |
KR20180055892A (ko) * | 2015-10-08 | 2018-05-25 | 온코세라피 사이언스 가부시키가이샤 | Mphosph1-유래 펩티드 및 이를 포함하는 백신 |
MA45489A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés de culture de cellules, kits et appareil associés |
MA45488A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés, kits et appareil de culture de cellules |
WO2017068419A2 (en) | 2015-10-22 | 2017-04-27 | Juno Therapeutics Gmbh | Methods, kits, agents and apparatuses for transduction |
WO2018070069A1 (ja) | 2016-10-11 | 2018-04-19 | サイトリミック株式会社 | 医薬 |
TW201831502A (zh) * | 2016-11-18 | 2018-09-01 | 日商腫瘤療法 科學股份有限公司 | 對於th1細胞的depdc1抗原決定位胜肽及包含其之疫苗 |
TW201831503A (zh) * | 2016-11-18 | 2018-09-01 | 日商腫瘤療法 科學股份有限公司 | 對於th1細胞的mphosph1抗原決定位胜肽及包含其之疫苗 |
WO2018094569A1 (zh) * | 2016-11-22 | 2018-05-31 | 深圳华大基因研究院 | 多肽及其应用 |
DK3573600T3 (da) | 2017-01-25 | 2022-05-09 | Ose Immunotherapeutics | Fremgangsmåde til fremstilling af en stabil emulsion til peptidlevering |
CN111032850A (zh) | 2017-04-27 | 2020-04-17 | 朱诺治疗学有限公司 | 寡聚粒子试剂及其使用方法 |
JP7274223B2 (ja) * | 2017-07-12 | 2023-05-16 | ノイスコム アーゲー | マイクロサテライト不安定性(msi)癌の予防及び治療のための共通腫瘍ネオアンチゲンをベースとした万能ワクチン |
RU2760984C1 (ru) | 2017-12-13 | 2021-12-02 | Иновио Фармасьютикалз, Инк. | Противораковые вакцины, направленные на lemd1, и их применение |
CN109932510B (zh) * | 2017-12-18 | 2022-07-12 | 天津云检医学检验所有限公司 | 一种宫颈癌生物标志物及其检测试剂盒 |
CN112142824B (zh) * | 2019-06-27 | 2022-03-11 | 深圳市东贵博康生化科技有限公司 | 具有诱导细胞毒性t淋巴细胞能力的多肽及其应用 |
WO2021060343A1 (ja) * | 2019-09-24 | 2021-04-01 | オンコセラピー・サイエンス株式会社 | Urlc10由来ペプチドまたはdepdc1由来ペプチドを認識するヒトt細胞が発現するt細胞受容体 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
HUT68510A (en) | 1991-08-26 | 1995-06-28 | Cytel Corp | Process for producing hla-restricted hapatitis b virus ctl epitopes and pharmaceutical compositions containing them |
ZA926441B (en) | 1991-08-26 | 1993-06-07 | Cytel Corp | HLA-restricted hepatitis B virus CTL epitopes. |
AU678225B2 (en) * | 1993-03-11 | 1997-05-22 | University Of Southern California | Therapeutic strategies for immunoinfective cluster virus infections |
US5804566A (en) | 1993-08-26 | 1998-09-08 | The Regents Of The University Of California | Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides |
US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
US5922687A (en) | 1995-05-04 | 1999-07-13 | Board Of Trustees Of The Leland Stanford Junior University | Intracellular delivery of nucleic acids using pressure |
US20030198642A1 (en) | 1995-08-03 | 2003-10-23 | Johannes J. Geuze | Cell derived antigen presenting vesicles |
US5853719A (en) | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
EP0960204A4 (en) | 1996-07-26 | 2002-01-23 | Sloan Kettering Inst Cancer | METHODS AND REAGENTS FOR GENETIC IMMUNIZATION |
FR2766205B1 (fr) | 1997-07-16 | 2002-08-30 | Inst Nat Sante Rech Med | Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede |
US7001999B1 (en) | 1998-04-15 | 2006-02-21 | Ludwig Institute For Cancer Research | Tumor associated nucleic acids and uses therefor |
MY139226A (en) * | 1998-09-30 | 2009-08-28 | Corixa Corp | Compositions and methods for wt1 specific immunotherapy |
US20050123938A1 (en) | 1999-01-06 | 2005-06-09 | Chondrogene Limited | Method for the detection of osteoarthritis related gene transcripts in blood |
US20040241726A1 (en) | 1999-01-06 | 2004-12-02 | Chondrogene Limited | Method for the detection of allergies related gene transcripts in blood |
US6291663B1 (en) | 1999-03-03 | 2001-09-18 | Board Of Trustees Of The University Of Arkansas | TADG-12: a novel transmembrane serine protease overexpressed in a ovarian carcinoma |
US7030215B2 (en) * | 1999-03-24 | 2006-04-18 | Sangamo Biosciences, Inc. | Position dependent recognition of GNN nucleotide triplets by zinc fingers |
AU5047800A (en) * | 1999-05-28 | 2000-12-18 | Ludwig Institute For Cancer Research | Breast, gastric and prostate cancer associated antigens and uses therefor |
ATE353366T1 (de) | 2000-08-22 | 2007-02-15 | Agensys Inc | Nukleinsäure und protein, genannt 158p1d7, für die behandlung und erkennung von blasenkrebs und anderen krebsarten |
WO2002031111A2 (en) | 2000-10-12 | 2002-04-18 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
EP1455816A4 (en) | 2000-10-19 | 2007-03-28 | Epimmune Inc | HLA CLASS I AND II BINDING PEPTIDES AND THEIR USE |
US7919467B2 (en) | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
WO2002046416A2 (en) * | 2000-12-04 | 2002-06-13 | Argonex Pharmaceuticals | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
US7078217B2 (en) * | 2002-01-31 | 2006-07-18 | Wyeth | Aggrecanase molecules |
AU2003222103A1 (en) | 2002-03-28 | 2003-10-13 | Idec Pharmaceuticals Corporation | Novel gene targets and ligands that bind thereto for treatment and diagnosis of colon carcinomas |
TW200413725A (en) | 2002-09-30 | 2004-08-01 | Oncotherapy Science Inc | Method for diagnosing non-small cell lung cancers |
US20060024692A1 (en) | 2002-09-30 | 2006-02-02 | Oncotherapy Science, Inc. | Method for diagnosing non-small cell lung cancers |
WO2005007090A2 (en) | 2003-07-03 | 2005-01-27 | President And Fellows Of Harvard College | Inhibitors of the map kinase pathway |
CA2580412A1 (en) | 2004-09-13 | 2006-03-23 | Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services | Compositions comprising t cell receptors and methods of use thereof |
EP2295601A1 (en) | 2005-02-10 | 2011-03-16 | Oncotherapy Science, Inc. | Method of diagnosing bladder cancer |
JP2006302684A (ja) | 2005-04-21 | 2006-11-02 | D D K Ltd | カードコネクタ |
EP2298895A1 (en) | 2005-07-27 | 2011-03-23 | Oncotherapy Science, Inc. | Method of diagnosing small cell lung cancer |
JP5276846B2 (ja) | 2005-09-13 | 2013-08-28 | 国立大学法人三重大学 | T細胞レセプターをコードする核酸が挿入されてなるベクター及び該レセプターを発現する細胞 |
US20070099251A1 (en) | 2005-10-17 | 2007-05-03 | Institute For Systems Biology | Tissue-and serum-derived glycoproteins and methods of their use |
TWM336439U (en) * | 2008-02-14 | 2008-07-11 | Optivision Technology Inc | Diffuser capable of light condensing |
JP5640263B2 (ja) | 2008-08-28 | 2014-12-17 | オンコセラピー・サイエンス株式会社 | Depdc1ポリペプチドを使用した膀胱癌の治療または予防のための方法 |
KR102015648B1 (ko) | 2011-08-12 | 2019-08-28 | 온코세라피 사이언스 가부시키가이샤 | Mphosph1 펩티드 및 이를 포함한 백신 |
-
2007
- 2007-10-16 CN CN201210305732.2A patent/CN102850435B/zh active Active
- 2007-10-16 KR KR1020147011020A patent/KR101493773B1/ko active IP Right Grant
- 2007-10-16 ES ES12155446.3T patent/ES2545818T3/es active Active
- 2007-10-16 EP EP20130189400 patent/EP2695895A1/en not_active Withdrawn
- 2007-10-16 SG SG10201502098YA patent/SG10201502098YA/en unknown
- 2007-10-16 ES ES07827901T patent/ES2415958T3/es active Active
- 2007-10-16 EP EP20130189408 patent/EP2687541A1/en not_active Withdrawn
- 2007-10-16 PT PT78279015T patent/PT2091965E/pt unknown
- 2007-10-16 KR KR1020147022451A patent/KR101543622B1/ko active IP Right Grant
- 2007-10-16 EP EP12155446.3A patent/EP2476698B1/en active Active
- 2007-10-16 MX MX2009004147A patent/MX2009004147A/es active IP Right Grant
- 2007-10-16 ES ES12155444.8T patent/ES2545817T3/es active Active
- 2007-10-16 AU AU2007311395A patent/AU2007311395B2/en not_active Ceased
- 2007-10-16 CN CN201210305211.7A patent/CN102850434B/zh active Active
- 2007-10-16 EP EP12155444.8A patent/EP2476697B1/en active Active
- 2007-10-16 CA CA2915560A patent/CA2915560A1/en not_active Abandoned
- 2007-10-16 DK DK07827901.5T patent/DK2091965T3/da active
- 2007-10-16 CN CN201210305207.0A patent/CN102850433B/zh active Active
- 2007-10-16 EP EP12155448.9A patent/EP2476699B1/en active Active
- 2007-10-16 CN CN2007800467286A patent/CN101568550B/zh active Active
- 2007-10-16 JP JP2009516776A patent/JP5339292B2/ja active Active
- 2007-10-16 KR KR1020157000123A patent/KR101527473B1/ko active IP Right Grant
- 2007-10-16 PL PL07827901T patent/PL2091965T3/pl unknown
- 2007-10-16 EP EP20130189390 patent/EP2687540A1/en not_active Withdrawn
- 2007-10-16 KR KR1020097010056A patent/KR101454287B1/ko active IP Right Grant
- 2007-10-16 EP EP07827901.5A patent/EP2091965B9/en active Active
- 2007-10-16 SG SG2011070455A patent/SG175566A1/en unknown
- 2007-10-16 CA CA2667030A patent/CA2667030C/en not_active Expired - Fee Related
- 2007-10-16 US US12/445,729 patent/US8557955B2/en active Active
- 2007-10-16 BR BRPI0717651-1A2A patent/BRPI0717651A2/pt not_active IP Right Cessation
- 2007-10-16 CN CN201610069574.3A patent/CN105693843A/zh active Pending
- 2007-10-16 RU RU2009118432/10A patent/RU2469044C2/ru not_active IP Right Cessation
- 2007-10-16 WO PCT/JP2007/001122 patent/WO2008047473A1/en active Application Filing
- 2007-10-16 ES ES12155448.9T patent/ES2545457T3/es active Active
-
2009
- 2009-04-16 IL IL198186A patent/IL198186A/en not_active IP Right Cessation
- 2009-11-23 HK HK09110942.9A patent/HK1131169A1/xx not_active IP Right Cessation
- 2009-11-23 HK HK12111316.0A patent/HK1171026A1/zh not_active IP Right Cessation
- 2009-11-23 HK HK12111315.1A patent/HK1171025A1/zh not_active IP Right Cessation
- 2009-11-23 HK HK12111314.2A patent/HK1171024A1/zh not_active IP Right Cessation
-
2011
- 2011-12-01 IL IL216713A patent/IL216713A0/en unknown
- 2011-12-01 IL IL216712A patent/IL216712A/en not_active IP Right Cessation
-
2012
- 2012-06-27 US US13/535,297 patent/US9017688B2/en active Active
- 2012-06-27 US US13/535,303 patent/US8653234B2/en active Active
- 2012-07-30 US US13/562,250 patent/US8552146B2/en active Active
- 2012-11-08 IL IL222925A patent/IL222925A0/en unknown
-
2013
- 2013-01-18 JP JP2013006870A patent/JP2013116115A/ja active Pending
-
2015
- 2015-03-24 US US14/667,560 patent/US9545437B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1171024A1 (zh) | 用於表達 多肽的癌症的肽疫苗 | |
IL221062A0 (en) | Stitched polypeptides | |
GB0721686D0 (en) | Polypeptides | |
IL219048A (en) | Peptide compounds derived from urcl10 | |
HK1135136A1 (en) | Natriuretic polypeptides | |
ZA200810738B (en) | Polypeptide | |
ZA201000283B (en) | Reinigung pegylierter polypeptide | |
GB0723712D0 (en) | Peptides | |
EP2123666A4 (en) | PEPTIDE | |
GB0725201D0 (en) | Peptide fusion proteins | |
GB0623539D0 (en) | Polypeptides | |
GB0712302D0 (en) | Chrondroitinase polypeptides | |
GB0703945D0 (en) | Peptide | |
GB0809659D0 (en) | Polypeptides | |
IL203073A0 (en) | Modified growth hormone polypeptides | |
IL197675A0 (en) | Peptides | |
EP2097439A4 (en) | NEW PEPTIDE | |
GB0708529D0 (en) | Peptide standards | |
GB0812586D0 (en) | Chimaeric peptide | |
GB0707626D0 (en) | Peptides | |
GB0705251D0 (en) | Peptides | |
GB0705115D0 (en) | Peptides | |
GB0609921D0 (en) | Peptides | |
GB0625176D0 (en) | Peptides | |
GB0609920D0 (en) | Peptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20221016 |